Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00126815
- Lead Sponsor
- AHS Cancer Control Alberta
- Brief Summary
Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
- Detailed Description
Clinical data (prostate-specific antigen \[PSA\] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1000
Inclusion Criteria
- Prostate cancer treated with radiotherapy +/- hormones
Exclusion Criteria
- Prostatectomy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PSA kinetics post-radiotherapy in prostate cancer models?
How does mathematical modeling of PSA response compare to standard-of-care treatment outcomes for localized prostate cancer?
Which biomarkers correlate with PSA decline patterns after radiotherapy in NCT00126815 data?
What adverse events are associated with radiotherapy-induced PSA fluctuations in prostate cancer patients?
How do combination therapies with radiotherapy influence PSA dynamics in hormone-sensitive prostate cancer?
Trial Locations
- Locations (1)
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada